These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Dai Y; Yu C; Singh V; Tang L; Wang Z; McInistry R; Dent P; Grant S Cancer Res; 2001 Jul; 61(13):5106-15. PubMed ID: 11431348 [TBL] [Abstract][Full Text] [Related]
3. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520 [TBL] [Abstract][Full Text] [Related]
4. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377 [TBL] [Abstract][Full Text] [Related]
5. Three-dimensional overlay culture models of human breast cancer reveal a critical sensitivity to mitogen-activated protein kinase kinase inhibitors. Li Q; Chow AB; Mattingly RR J Pharmacol Exp Ther; 2010 Mar; 332(3):821-8. PubMed ID: 19952304 [TBL] [Abstract][Full Text] [Related]
6. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. Mody N; Leitch J; Armstrong C; Dixon J; Cohen P FEBS Lett; 2001 Jul; 502(1-2):21-4. PubMed ID: 11478941 [TBL] [Abstract][Full Text] [Related]
7. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors. Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676 [TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors restore anoikis sensitivity in human breast cancer cell lines with a constitutively activated extracellular-regulated kinase (ERK) pathway. Fukazawa H; Noguchi K; Murakami Y; Uehara Y Mol Cancer Ther; 2002 Mar; 1(5):303-9. PubMed ID: 12489846 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK pathway in vestibular schwannoma cell culture. Neff BA; Voss SG; Schmitt WR; Driscoll CL; Link MJ; Beatty CW; Kita H Laryngoscope; 2012 Oct; 122(10):2269-78. PubMed ID: 22886786 [TBL] [Abstract][Full Text] [Related]
10. Cell-cycle arrest by PD184352 requires inhibition of extracellular signal-regulated kinases (ERK) 1/2 but not ERK5/BMK1. Squires MS; Nixon PM; Cook SJ Biochem J; 2002 Sep; 366(Pt 2):673-80. PubMed ID: 12069688 [TBL] [Abstract][Full Text] [Related]
11. [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment]. Zhang YX; Kong CZ Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):271-5. PubMed ID: 18361842 [TBL] [Abstract][Full Text] [Related]
12. Effect of inhibitors of mitogen-activated protein kinase kinase on alpha(1B)-adrenoceptor phosphorylation. Alcántara-Hernández R; Adolfo García-Sáinz J Auton Autacoid Pharmacol; 2009 Jan; 29(1-2):13-23. PubMed ID: 19302552 [TBL] [Abstract][Full Text] [Related]
13. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation. Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122 [TBL] [Abstract][Full Text] [Related]
14. Ras pathway activation in malignant mesothelioma. Patel MR; Jacobson BA; De A; Frizelle SP; Janne P; Thumma SC; Whitson BA; Farassati F; Kratzke RA J Thorac Oncol; 2007 Sep; 2(9):789-95. PubMed ID: 17805054 [TBL] [Abstract][Full Text] [Related]
15. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228 [TBL] [Abstract][Full Text] [Related]
16. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Woessmann W; Chen X; Borkhardt A Cancer Chemother Pharmacol; 2002 Nov; 50(5):397-404. PubMed ID: 12439598 [TBL] [Abstract][Full Text] [Related]
17. Restoration of IRF1-dependent anticancer effects by MEK inhibition in human cancer cells. AbuSara N; Razavi S; Derwish L; Komatsu Y; Licursi M; Hirasawa K Cancer Lett; 2015 Feb; 357(2):575-81. PubMed ID: 25497010 [TBL] [Abstract][Full Text] [Related]
18. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Yip-Schneider MT; Schmidt CM Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498 [TBL] [Abstract][Full Text] [Related]
19. Transfected beta3- but not beta2-adrenergic receptors regulate cystic fibrosis transmembrane conductance regulator activity via a new pathway involving the mitogen-activated protein kinases extracellular signal-regulated kinases. Robay A; Toumaniantz G; Leblais V; Gauthier C Mol Pharmacol; 2005 Mar; 67(3):648-54. PubMed ID: 15563584 [TBL] [Abstract][Full Text] [Related]
20. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]